See related links to what you are looking for.
Total raised: $156.5M
Investors 1
| Date | Name | Website |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 09.12.2014 | - | $50M | - |
| 01.03.2013 | Series E | $48M | - |
| 21.09.2011 | Series E | $44M | - |
| 16.07.2008 | - | $14.5M | - |
Mentions in press and media 14
| Date | Title | Description |
| 10.12.2014 | Heart failure startup CardioKinetix gets $50M in round led by Edwards Lifesciences | The device received the ubiquitous European CE Mark in 2011, but is still an investigational device in the U.S. Existing investors U.S. Venture Partners, Tekla Healthcare Investors, SV Life Sciences, Panorama Capital, New Leaf Venture Partn... |
| 09.12.2014 | CardioKinetix Completes $50M Financing | CardioKinetix, Inc., a Menlo Park, Calif.-based medical device company, completed a $50m financing. The round was led by Edwards Lifesciences Corporation, with participation from existing investors U.S. Venture Partners, Tekla Healthcare In... |
| 09.12.2014 | CardioKinetix Completes $50M Financing | MENLO PARK, CA, Medical device company pioneering a catheter-based treatment for heart failure, announced today that it has completed a $50 million financing. >> Click here for more funding data on CardioKinetix >> To export... |
| 08.12.2014 | CardioKinetix raises $50m, inks buyout deal with Edwards Lifesciences | CardioKinetix said it signed an exclusive option-to-buy agreement with Edwards Lifesciences (NYSE:EW) in connection with a $50 million financing round. The cardiac device company said that Edwards will have the right to purchase CardioKinet... |
| 01.03.2013 | CardioKinetix Completes $23M Second Tranche of Series E Financing | CardioKinetix Inc., a Menlo Park, CA-based medical device company developing a catheter-based treatment for heart failure, completed the $23m second-tranche of its Series E financing. This funding, which brings the total amount raised in th... |
| 28.02.2013 | CardioKinetix Completes $48M in Series E | MENLO PARK, CA, Medical device company pioneering a catheter-based treatment for heart failure, announced today that it has completed the $23 million second-tranche of its Series E financing. >> Click here for more funding data on ... |
| 28.02.2013 | CardioKinetix closes $23M tranche in $48M Series E round | CardioKinetix said it’s raised $48 million in its Series E round with the closure of a 2nd tranche worth $23 million and plans to use the proceeds to further its Parachute ventricular partitioning device, which is in a pivotal trial. The Me... |
| 09.05.2012 | 5 cardiovascular disease medical device companies to watch | “The aging of the population and the near epidemic of obesity and type 2 diabetes even in the younger population will prolong this trend and sustain potential in this market for a long time to come,” said Kenneth Krul, author of a cardiovas... |
| 21.09.2011 | Ning, Rearden, Adchemy, ArcSoft & More: The Bay Area Deals Roundup, By the Numbers | Share Share on Facebook Share on Twitter LinkedIn Email Reprints The venture funding and merger & acquisition news flies so fast in Silicon Valley that we have a bit of trouble keeping up, to be frank. We’re experimenting with different... |
| 21.09.2011 | CardioKinetix Pulses To $44M Series E | The financing was led by new investors SV Life Sciences and New Leaf Venture Partners, who joined existing investors, including U.S. Venture Partners, J.P. Morgan Partners, H&Q Healthcare Investors and H&Q Life Sciences Investors.... |
Show more